GTBP

GT Biopharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing and commercializing novel immuno-oncology therapies for cancer treatment. Headquartered in Los Angeles, California, the company concentrates on innovative therapeutic approaches utilizing natural killer (NK) cell-based platforms and antibody-drug conjugates. GT Biopharma's lead product candidate, GTB-3550, represents a bispecific antibody designed to engage natural killer cells to target CD33-expressing tumors, including acute myeloid leukemia and other hematologic malignancies. The company's pipeline also includes GTB-5550, a fusion protein combining an antibody-drug conjugate with an NK cell engager. GT Biopharma evolved from its predecessor Oxis International and underwent significant transformation following its 2020 merger with GTx-2 Therapeutics. The company maintains strategic partnerships and collaborations to advance its clinical programs through various trial phases. As a development-stage enterprise, GT Biopharma currently generates minimal revenue and directs resources toward research and development activities. The company's approach emphasizes harnessing the immune system's natural killer cells, distinguishing its therapeutic strategy from traditional chemotherapy and other immunotherapy modalities. GT Biopharma's securities trade on the NASDAQ Capital Market under the ticker symbol GTBP, providing public market access to investors interested in the immuno-oncology sector.